Statistical methods in oncology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
Log-rank test
Cochran-Mantel-Haenszel test
Odds ratio
Cox proportional-hazards model
Fisher exact test
Risk difference
Stratified log-rank test
All oncology trials
2,067 results
- BRUOG-407Independent statistical analysis of Removing Transfusion Dependence as a Barrier to Hospice Enrollment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05063591).
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): Complete Statistical AnalysisIndependent statistical analysis of BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Busulfan and Cyclophosphamide Followed By ALLO BMT: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Cyclophosphamide Followed By ALLO BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01685411).
- Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00800839).
- Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): Complete Statistical AnalysisIndependent statistical analysis of Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361140).
- Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264131).
- BYLieveIndependent statistical analysis of the phase 2 BYLieve trial of alpelisib-based treatment in PIK3CA-mutant, HR+, HER2- advanced breast cancer, including trial design, the primary binary endpoint, planned analysis, statistical interpretation, and safety.
- C-TRAK TNIndependent statistical analysis of C-TRAK TN, a randomized phase 2 trial evaluating ctDNA-guided treatment in early-stage triple-negative breast cancer, including trial design, endpoints, planned statistical methods, and interpretation.
- Cabergoline in Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabergoline in Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01730729).
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Cabozantinib for Adults With Advanced Soft Tissue Sarcoma: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib for Adults With Advanced Soft Tissue Sarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01755195).
- Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04631744).
- Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: Complete Statistical AnalysisIndependent statistical analysis of Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00258960).
- CairnSurgical Breast Cancer Locator (BCL) Post-Market Study: Complete Statistical AnalysisIndependent statistical analysis of CairnSurgical Breast Cancer Locator (BCL) Post-Market Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06461663).
- CAIRO2Independent statistical analysis of CAIRO2, a randomized phase 3 trial of capecitabine, oxaliplatin and bevacizumab with or without cetuximab in advanced colorectal cancer. Covers trial design, endpoints, planned statistical methods, interpretation, and…
- CAIRO3Independent statistical analysis of the CAIRO3 phase 3 trial evaluating capecitabine plus bevacizumab maintenance treatment versus observation after induction in advanced colorectal carcinoma.
- CALGB 9344Independent statistical analysis of CALGB 9344 (NCT00991263), including trial design, disease-free survival endpoint, planned statistical methodology, and interpretation of the registry record.
- CALGB 9633An independent statistical analysis of CALGB 9633, a randomized phase 3 trial of surgery with or without paclitaxel and carboplatin chemotherapy in patients with stage IB non-small cell lung cancer.
- CALIPSOIndependent statistical analysis of CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CALMextIndependent statistical analysis of CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext): primary endpoint results, effect estimate with confidence interval, sample-size…
- CANOPY-2Independent statistical analysis of Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy:…
- Canopy-AComplete statistical analysis of the phase 3 Canopy-A trial of canakinumab versus placebo as adjuvant therapy in completely resected non-small cell lung cancer, including disease-free survival, subgroup analyses, statistical methodology, safety, and…
- CANTATAIndependent statistical analysis of CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- CAO/ARO/AIO-04Independent statistical analysis of the randomized phase 3 CAO/ARO/AIO-04 trial of 5-fluorouracil and oxaliplatin versus 5-fluorouracil in rectal cancer, including trial design, disease-free survival methodology, endpoint definitions, and statistical interpretation.
- CAO/ARO/AIO-12An independent statistical analysis of the randomized phase 2 CAO/ARO/AIO-12 trial comparing the sequence of induction chemotherapy and preoperative chemoradiotherapy before surgery for locally advanced rectal cancer.
- CAP’ONCOIndependent statistical analysis of CAP'Onco : Psychological and Social Consultation of Professional Accompaniment in Oncology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00565370).
- Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00347438).
- Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction: primary endpoint results, effect estimate with confidence…
- Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.
- Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00514540).
- Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: Complete Statistical AnalysisIndependent statistical analysis of Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…